The Pew Charitable Trusts announced that 22 early-career researchers have been selected to join the Pew Scholars in the Biomedical Sciences. Among them are Seth Shipman, PhD, assistant investigator at Gladstone Institutes, who will receive 4 years of funding to invest in foundational research to pursue scientific breakthroughs and advance human health.
“Pew is proud to support these promising researchers as they conduct world-class research to address biomedicine’s most complex questions,” said Rebecca W. Rimel, Pew’s president and CEO, in a news release. “They join a group of distinguished scientists who have worked for decades to advance science and protect public health.”
Shipman was selected to develop a novel method for introducing engineered DNA sequences into living cells. This technology will change the way scientists record molecular events within cells, enable the design of new therapies to alter the progression of cancer, and lead to methods to repair elements of the genome that are damaged in genetic diseases such as hemophilia.
“Seth takes an innovative approach to his research by focusing on developing new tools and technologies to address unanswered questions in neuroscience,” says Gladstone President Deepak Srivastava, MD. “He is an incredibly creative rising star, and we’re excited to see where his work will lead.”
The 2020 class of scholars—all of whom hold assistant professor positions—were chosen from 191 applicants nominated by leading academic institutions and researchers across the United States. They are new members of a vibrant community of more than 1,000 scientists who have received awards from Pew since 1985. Current scholars meet annually to share their research and exchange perspectives across diverse health disciplines.
Seth Shipman is recognized for his exceptionally creative research approachAwards News Release Data Science and Biotechnology Shipman Lab
Leor Weinberger is selected by the National Institute on Drug Abuse for his innovative HIV researchAwards HIV/AIDS Weinberger Lab